Peptide Library

In clinical trials

Heart & blood

Selepressin

Evidence

Clinical trials

Class

Selective V1a receptor agonist

/

Selepressin

KEY TAKEAWAY

Selepressin is a synthetic vasopressin analog designed to act only on the V1a receptor. Selepressin is not FDA-approved. A large trial in septic shock was stopped in 2017 because it was unlikely to show benefit.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Selective V1a receptor agonist

Being studied for

Studied in septic shock

Key fact

Selepressin is not FDA-approved. A large trial in septic shock was stopped in 2017 because it was unlikely to show benefit.

Route

Intravenous infusion in trials

Evidence strength

Clinical trials

What it is

What it is

Selepressin is a synthetic vasopressin analog designed to act only on the V1a receptor.

How it works

How it works

It narrows blood vessels without the water-retaining effects of vasopressin, which was meant to help treat septic shock.

Regulatory status

Regulatory status

Selepressin is not FDA-approved. A large trial in septic shock was stopped in 2017 because it was unlikely to show benefit.

What it is used for

What it is used for

Studied in septic shock.

Side effects and risks

Side effects and risks

In trials, side effects were similar to standard care, but the drug did not improve outcomes.

Citations

Citations

Selepressin: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo